Liraglutide, a human glucagon-like peptide-1 analogue, plays a role in reducing body weight in the patients with type 2 diabetes / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism
; (12): 703-706, 2011.
Article
em Zh
| WPRIM
| ID: wpr-424193
Biblioteca responsável:
WPRO
ABSTRACT
Obesity is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Losing weight is an effective way of improving insulin sensitivity, thus decreasing the risk of obesityassociated diabetes and chronic cardiovascular disease. There is evidence that Liraglutide, as a human glucagon-like peptide-1 ( GLP-1 ) analogue, either using alone or combining with other glucose-lowering drugs, has effect on improving glycemic control, protecting β-cell function, and reducing body weight via inhibiting feeding behavior and delaying gastrointestinal motility. Therefore, liraglutide is a new option for treating type 2 diabetes patients.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Endocrinology and Metabolism
Ano de publicação:
2011
Tipo de documento:
Article